Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and treatment regimens across ERS SHARP severe asthma registries.
van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, Dahlén B, Davin E, Hansen S, Heffler E, Horvath I, Korn S, Kots M, Kuna P, Kwon N, Louis R, Plaza V, Porsbjerg C, Ramos-Barbon D, Richards LB, Škrgat S, Sont JK, Vijverberg SJH, Weersink EJM, Yasinska V, Wagers SS, Djukanovic R, Maitland-van der Zee AH; SHARP Clinical Research Collaboration; Members of the SHARP Clinical Research Collaboration are. van Bragt JJMH, et al. Eur Respir J. 2020 Jan 9;55(1):1901163. doi: 10.1183/13993003.01163-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31601713 Free article.
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
Howarth P, Chupp G, Nelsen LM, Bradford ES, Bratton DJ, Smith SG, Albers FC, Brusselle G, Bachert C. Howarth P, et al. Among authors: smith sg. J Allergy Clin Immunol. 2020 Jun;145(6):1713-1715. doi: 10.1016/j.jaci.2020.02.002. Epub 2020 Feb 19. J Allergy Clin Immunol. 2020. PMID: 32084443 Clinical Trial. No abstract available.
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Han JK, et al. Among authors: smith sg. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872587
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). McDowell PJ, et al. Lancet Respir Med. 2021 Oct;9(10):1174-1184. doi: 10.1016/S2213-2600(21)00004-7. Epub 2021 May 7. Lancet Respir Med. 2021. PMID: 33971168
Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
Lugogo N, Liu MC, Pavord I, Mitchell PD, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Bel EH. Lugogo N, et al. Among authors: smith sg. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3506-3509.e3. doi: 10.1016/j.jaip.2021.05.024. Epub 2021 Jun 7. J Allergy Clin Immunol Pract. 2021. PMID: 34111572 Free article. No abstract available.
548 results